VEGFA and choroidal neovascularization: There is currently no highly efficacious approved treatment for atrophic AMD, despite the involvement of complement, inflammatory factors, and oxidative stress, whereas agents that interfere with angiogenic factors (e.g., vascular endothelial growth factor [VEGF]) are used for neovascular AMD to reduce vision-threatening macular or choroidal neovascularization (CNV) [4,5,6].